Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy
Correspondence to: Bruno Linetzky, Eli Lilly and Company, Tronador 4890 Piso 12, Buenos Aires, Argentina, C1430 DNN. Email Diabetes Complications Research Centre, Conway Institute, University College Dublin, Ireland (C.W.l.R.). Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, OH (L.J.L.). Obesity is a risk factor for hypertension and cardiovascular disease. In SURMOUNT-1, tirzepatide, the glucose-dependent insulinotropic polypeptide/GLP-1 (glucagon-like peptide-1) receptor